Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), talks about the impact that finerenone could have on patients with kidney disease and diabetes.
Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), talks about the impact that finerenone, a drug that was added to the ADA's list of recommended drugs for chronic kidney disease (CKD) management, could have on patients with CKD and diabetes.
What impact do you think adding Kerendia (finerenone) as a recommended medication for the CKD and diabetes populations will have on patient experience?
We're driven by improving the lives of people affected by diabetes. And so, the underlying reason for doing this standards of care is really to help guide clinicians in the best care of their patients. And finerenone is a new treatment that can significantly improve outcomes for people with diabetes. Our hope is that these standards helped to bring the attention to clinicians about this new treatment option.